Fundraising FoxBioBrit — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Co-investorsAlumni VenturesF-Prime CapitalForesite CapitalGV (Google Ventures)OrbiMedvenBio Partners+3 more
Exact Sciences develops and runs laboratory tests and clinical studies for cancer detection and treatment, serving patients and health care professionals in oncology.
BiotechDigital HealthMedical DevicesSan Diego, US
Tony Broad(Executive Officer)Francois Ferre(Director)Nick Ecos(Executive Officer, Director)Joseph Markee(Executive Officer, Director)
Co-investorsIn-Q-TelMESA VERDE VENTURE PARTNERS
Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure.
BiotechHealthtechLongevityMedical DevicesBlackfalds
Roger Bergersen(Founder (of predecessor TheraVitae Inc.))Thomas A. Smeenk(President & CEO, Co-Founder)inIna Sarel(VP, Research and Development)inKyle Makofka(Chief Restructuring Officer)inDavid Berman(Chief Financial Officer)Dr. Fraser Henderson(Chief Medical Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.